Zentalis Pharmaceuticals (ZNTL) Gains from Investment Securities (2019 - 2025)
Zentalis Pharmaceuticals' quarterly Gains from Investment Securities came in at -$634000.0 in Q4 2025, down 715.53% quarter-over-quarter from $103000.0 in Q3 2025.
Zentalis Pharmaceuticals has reported Gains from Investment Securities for 6 years, with the latest figure at -$634000.0 in Q4 2025.
- For the quarter ending Q4 2025, Gains from Investment Securities changed N/A year-over-year to -$634000.0; the trailing twelve-month figure through Sep 2025 stood at $634000.0 (up 3.76% YoY), and the FY2024 full-year result was $13000.0, down 97.84% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at -$634000.0, down from $103000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $44.6 million in Q4 2021, with the low at -$634000.0 in Q4 2025.
- Average Gains from Investment Securities over 5 years is $3.8 million, with a median of $35000.0 recorded in 2023.
- Year-over-year, Gains from Investment Securities slumped 1425.0% in 2024 and soared 1101.89% in 2025.
- Tracing ZNTL's Gains from Investment Securities over 5 years: stood at $44.6 million in 2021, then slumped by 100.15% to -$68000.0 in 2022, then soared by 979.41% to $598000.0 in 2023, then plunged by 108.86% to -$53000.0 in 2024, then sank by 1096.23% to -$634000.0 in 2025.
- The last three Gains from Investment Securities figures came in at -$634000.0 (Q4 2025), $103000.0 (Q3 2025), and $531000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Zentalis Pharmaceuticals | 280.35 Mn | 280.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -634,000.00 |
| Dec 31, 2025 | -634,000.00 |
| Sep 30, 2025 | 103,000.00 |
| Sep 30, 2025 | 103,000.00 |
| Jun 30, 2025 | 531,000.00 |
| Jun 30, 2025 | 531,000.00 |
| Jun 30, 2024 | -53,000.00 |
| Jun 30, 2024 | -53,000.00 |
| Mar 31, 2024 | 66,000.00 |
| Mar 31, 2024 | 66,000.00 |
| Dec 31, 2023 | 598,000.00 |
| Dec 31, 2023 | 598,000.00 |
| Jun 30, 2023 | 4,000.00 |
| Jun 30, 2023 | 4,000.00 |
| Dec 31, 2022 | -68,000.00 |
| Dec 31, 2022 | -68,000.00 |
| Sep 30, 2022 | 125,000.00 |
| Sep 30, 2022 | 125,000.00 |
| Jun 30, 2022 | -57,000.00 |
| Jun 30, 2022 | -57,000.00 |
| Dec 31, 2021 | 44.63 Mn |
| Dec 31, 2021 | 44.63 Mn |
| Mar 31, 2021 | -15,000.00 |
| Mar 31, 2021 | -15,000.00 |
| Sep 30, 2019 | -1.26 Mn |
| Sep 30, 2019 | -1.26 Mn |
| Jun 30, 2019 | 1.31 Mn |
| Jun 30, 2019 | 1.31 Mn |
| Mar 31, 2019 | 1.37 Mn |
| Mar 31, 2019 | 1.37 Mn |